Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now

You can switch off notifications anytime using browser settings.
Stock Analysis, IPO, Mutual Funds, Bonds & More

Dr Reddy’s agrees to buy UCB business in India for Rs 800 crore

The deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement to the Bombay Stock Exchange.

, ET Bureau|
Updated: Apr 01, 2015, 01.41 PM IST
DRL to buy UCB brands for Rs 800 crore
HYDERABAD: Dr Reddy’s Laboratories, India’s second largest drugmaker by sales, has announced entering into a definitive agreement to acquire a select portfolio of Belgium based pharmaceutical firm UCB in India for Rs 800 crore.

UCB, listed on Euronext Brussels, has operations in nearly 40 countries with revenues of 3.3 billion Euros in 2014. In a statement on Wednesday, the Hyderabad headquartered drugmaker said the established products business of UCB would cover the territories of India, Nepal, Sri Lanka and Maldives and the acquisition is on a slump sale basis.

Dr Reddy’s said the transaction includes approximately 350 employees engaged in operations of UCB’s India business and the revenue of the acquired business was approximately Rs 150 crore for calendar year 2014.

The Indian drugmaker said the acquisition of UCB’s existing brand equity in the areas of dermatology, respiratory and paediatrics diseases will further expand Dr Reddy’s therapy footprint into these fast growing areas. The transaction is expected to be closed in the first quarter of the financial year 2015-16.

"The acquired UCB portfolio shall accelerate Dr Reddy’s presence in the high growth areas of dermatology, respiratory and paediatrics with market leading brands like Atarax, Nootropil, Zyrtec, Xyzal, Xyzal M etc," said Alok Sonig, Senior Vice President and India Business Head.

UCB’s chief operating officer Mark McDade said, "Finding the right company for our established brands in India was crucial, and Dr. Reddy’s knowledge of the local market, combined with their ambitious plans and excellent reputation, convinced us they were the right choice to drive this business forward."

Further, he said, UCB was in a strong position with a solid platform for continuous growth thanks to its core products and its promising pipeline. "This position allows us to enhance our focus on our key neurology portfolio in India, providing innovative solutions to patients living with severe diseases."

Also Read

UCBs with PMC Deposits must be given time for provisioning, NGO writes to FinMin

Amazon Freedom Sale: Huge discounts on Puma, UCB; affordable clothing, footwear under Rs 499

Improve governance practices or perish: RBI to UCBs

UCBs allowed secondary market non-SLR investments with non-bank participants

Permission for new branches for UCBs only after amending bye-laws to set up a Board of Management

Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Sensex, Stock Market Updates & More.

Other useful Links

Follow us on

Download et app

Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service